Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 4 records in total 4
    records per page

    IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases MESHD with tissue inflammation MESHD

    Authors: Lorien Shakib; Sara Shanaj; Aparna Nathan; - Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus; Laura T. Donlin

    doi:10.1101/2020.08.05.238360 Date: 2020-08-05 Source: bioRxiv

    Immunosuppressive and anti-cytokine treatment may have a protective effect for patients with COVID-19. Understanding the immune cell states shared between COVID-19 and other inflammatory diseases MESHD with established therapies may help nominate immunomodulatory therapies. Using an integrative strategy, we built a reference by meta-analyzing > 300,000 immune cells from COVID-19 and 5 inflammatory diseases MESHD including rheumatoid arthritis MESHD rheumatoid arthritis HP (RA), Crohn disease MESHD (CD), ulcerative colitis MESHD ulcerative colitis HP (UC), lupus, and interstitial lung disease MESHD. Our cross- disease MESHD analysis revealed that an FCN1+ inflammatory macrophage state is common to COVID-19 bronchoalveolar lavage samples, RA synovium, CD ileum, and UC colon. We also observed that a CXCL10+ CCL2+ inflammatory macrophage state is abundant in severe COVID-19, inflamed CD and RA, and expresses inflammatory genes such as GBP1, STAT1, and IL1B. We found that the CXCL10+ CCL2+ macrophages are transcriptionally similar to blood SERO-derived macrophages stimulated with TNF- and IFN-{gamma} ex vivo. Our findings suggest that IFN-{gamma}, alongside TNF-, might be a key driver of this abundant inflammatory macrophage phenotype in severe COVID-19 and other inflammatory diseases MESHD, which may be targeted by existing immunomodulatory therapies.

    Ulcerative Colitis MESHD Ulcerative Colitis HP Developed in a COVID-19 Patient: A Case Report

    Authors: Muhammet Fatih Aydin; Hamit Tasdemir

    doi:10.21203/ Date: 2020-06-29 Source: ResearchSquare

    Background: COVID-19 pneumonia MESHD pneumonia HP is a widespread viral disease MESHD, which affects all the world and has been accepted as pandemic by the World Health Organization (WHO). Coronavirus can remain in the stool for certain time even after recovery from COVID-19 pneumonia MESHD pneumonia HP in some infected patients. Studies increasingly report involvement of other organs including gastrointestinal system in addition to respiratory symptoms in COVID-19. Ulcerative colitis MESHD Ulcerative colitis HP is an inflammatory bowel disease MESHD with unknown cause. Emerging data suggest that gastrointestinal system may also be influenced by COVID-19 based via the expression of ACE-2. However, data abour the association of COVID-19 and inflammatory bowel diseases MESHD including ulcerative colitis MESHD ulcerative colitis HP are lacking. Case Presentation: In this report, we present a case of ulcerative colitis MESHD ulcerative colitis HP diagnosed in a 50-year-old male TRANS patient who presented with the complaints of bloody diarrhea HP diarrhea MESHD and abdominal pain MESHD abdominal pain HP following the completion of the treatment of COVID-19 pneumonia MESHD pneumonia HP. Conclusion: Patients presenting with gastrointestnal complaints should also be evaluated for COVID-19.

    Infliximab Attenuates Paediatric Inflammatory Multisystem Syndrome MESHD in SARS-CoV-2 (PIMS-TS)

    Authors: Joseph Meredith; Cher-Antonia Khedim; Paul Henderson; David C. Wilson; Richard K. Russell

    id:10.20944/preprints202006.0118.v1 Date: 2020-06-09 Source:

    Paediatric inflammatory multisystem syndrome MESHD temporally associated with SARS-CoV-2 (PIMS-TS) is a newly described condition. It has a spectrum of presentations related to hyperinflammation and cytokine storm. We report the first case of PIMS-TS in a child TRANS on established anti-Tumor Necrosis MESHD Factor-alpha (anti-TNF-α) therapy; a 10 year-old girl with ulcerative colitis MESHD ulcerative colitis HP treated with infliximab. The patient had 6-weeks of daily fever MESHD fever HP with mucocutaneous, gastrointestinal, renal and hematologic involvement. Biomarkers of hyperinflammation were present including: hyperferritinaemia (up to 691 µ/L; normal 15-80 µg/L), C-reactive protein (CRP) (>100mg/L for >10 days, normal 0-5 mg/L), erythrocyte sedimentation rate (ESR) consistently >100mm/hr (normal 0-15 mm/hr), raised white cell count with neutrophilia HP, elevated D-dimer and lactate dehydrogenase (LDH), anaemia and Mott cells on bone marrow analysis. Extensive investigations for alternative diagnoses for pyrexia of unknown origin (PUO) were negative. The condition was refractory to treatment with intravenous immunoglobulin (IVIG) but improved within 24hrs of high dose methylprednisolone. Infliximab treatment followed and the patient has remained well at follow up. Polymerase chain reaction (PCR) and serology for SARS-CoV-2 were negative. Current series report such negative findings in up to half of cases. The patient experienced a milder clinical phenotype without cardiac involvement, shock MESHD shock HP or organ failure. It is postulated that prior anti-TNF-α therapy attenuated the disease MESHD course. Infliximab therapy may interfere with serology testing and produce false negative results. This case supports the need for investigation into infliximab as primary therapy for PIMS-TS.

    Questionnaire assessment helps the self-management of patients with inflammatory bowel disease MESHD during the outbreak of Coronavirus Disease MESHD 2019

    Authors: Meiping Yu; Zhenghao Ye; Yu Chen; Tingting Qin; Jiguang Kou; Dean Tian; Fang Xiao

    doi:10.1101/2020.03.25.20043364 Date: 2020-03-27 Source: medRxiv

    Background and Aims: The outbreak of Coronavirus Disease MESHD 2019 (COVID-19) may affect the disease MESHD status of patients with inflammatory bowel disease MESHD (IBD). This study aimed to assess the disease MESHD status of IBD patients in Hubei province by questionnaire online and guide to the self-management of IBD patients during this epidemic. Methods: A questionnaire was designed containing the Harvey-Bradshaw Index (HBI), the Partial Mayo Score (PMS), the short inflammatory bowel disease MESHD questionnaire (SIBDQ) and distributed to Hubei IBD patients online within one month of traffic control after the outbreak of COVID-19. This questionnaire also included some questions about patients' self-report disease MESHD conditions and their epidemiological history of COVID-19. Results: A total of 102 eligible questionnaires were included in the analysis. No patient reported infection MESHD infection with severe HP with severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) in our study. Our result showed that 69.64% of patients with ulcerative colitis MESHD ulcerative colitis HP (UC) and 80.44% of patients with Crohn's disease HP disease MESHD (CD) were in remission. There was not a statistically significant difference in the proportion of the active disease MESHD stage between the two types of disease MESHD (p=0.103). The majority of patients (85.29%) had a good health-related quality of life (HRQoL) (SIBDQ[≥]50). The reduction in physical exercise is a risk factor for worsening in conditions (OR=17.593, 95%CI 2.035 to 152.097, p=0.009). Conclusions: The outbreak of COVID-19 might not have a significant impact on most Hubei IBD patients within one month after the traffic control. The patient's disease MESHD condition could be assessed by our questionnaires. Doctors utilized the information and advised for IBD patients about self-management during the period of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.